AlphAIAlphAI — Financial news for AI agents
seekingalpha.comSEP 221 min read$CLDX

Celldex stock falls after hives trial data (CLDX:NASDAQ)

Celldex (CLDX) shares fell over 20% premarket Tuesday despite positive late-stage trial results for barzolvolimab, its experimental hives treatment, according to the company.

Original reporting
seekingalpha.com
Published Sep 22, 2026, 12:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 12:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$CLDX
Bearish
high confidence
Mentioned
$CLDX
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$CLDXBearishHigh
01

Why it matters

The trial data is the first public disclosure, triggering a sharp pre‑market sell‑off despite the positive outcome.

02

Market read

First report of pivotal trial results; significant price move indicates high trading relevance.

03

What to watch

Potential partnership or licensing deals not yet disclosed.

Relevance 8/10Novelty 9/10Timing: premarket today

Background

Celldex (NASDAQ:CLDX) is a New Jersey‑based biotech focused on dermatology therapies.

Company-level read

Ticker impact

$CLDXBearishHigh confidence
Context

Celldex announced positive Phase 3 trial results for barzolvolimab, causing a >20% pre‑market drop.

Expected impact

Further downside risk if investors remain skeptical; potential rebound if data leads to regulatory filing.

Evidence & confidence

First disclosure of trial outcomes; market moved sharply, indicating high trader interest.

Market effects

Sector

May pressure other biotech firms with similar dermatology pipelines.

Regional

Limited to US biotech sector.

Global

Minimal beyond specialty pharma investors.

Counterpoint

What could challenge this read

Positive data could eventually drive a rally if pricing concerns are resolved.

Key entities

  • Company
    Celldex Therapeutics

    Biotech developer of barzolvolimab.

Read at source← All news

Related articles

SEP 23
$CLDXMedAI 8/10

Celldex Therapeutics Leads Guggenheim’s Biotechnology Rankings

Guggenheim's biotech rankings place Celldex Therapeutics (CLDX) at the top due to positive Phase III trial results for barzovolimab in treating chronic spontaneous urticaria. The drug showed strong efficacy and a low rate of severe anaphylaxis. CLDX recently discontinued a prurigo nodularis study after it failed to meet endpoints. Analysts have mixed price target adjustments.

investing.com2 min
SEP 23
$CLDXHighAI 9/10

Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?

Celldex Therapeutics (CLDX) reported positive Phase 3 trial results for barzolvolimab in chronic spontaneous urticaria, meeting all primary and secondary endpoints. The drug showed significant efficacy, with a majority of patients achieving complete symptom relief. However, the company faces high R&D costs and a 2027 expected BLA filing. CLDX has $717.6M in cash and a pipeline of other studies, but a recent Phase 2 failure in prurigo nodularis highlights risks.

insidermonkey.com3 min
SEP 22
$CLDXHighAI 8/10

Why is Celldex Therapeutics stock sliding today?

Celldex Therapeutics (CLDX) stock fell 10.4% after Phase 3 trial results for barzolvolimab met primary and secondary endpoints but showed smaller efficacy gains than Phase 2. Analysts maintained positive ratings and price targets. The broader market had minimal impact, highlighting the company-specific move.

investing.com2 min
SEP 22
$CLDXMedAI 9/10

CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’

Celldex Therapeutics (CLDX) stock fell 11% despite positive Phase 3 trial results for Barzolvolimab, its treatment for chronic spontaneous urticaria. H.C. Wainwright raised its price target to $64, citing nearly 90% upside potential. The studies met primary and secondary endpoints, but safety concerns, including two cases of probable Grade 4 anaphylaxis, led to the initial sell-off. Celldex plans to file for FDA approval in 2027.

stocktwits.com2 min